How to Evaluate a Peptide Supplier for Your Medical Practice

A practice evaluates a supplier by establishing what it is before comparing price

This guide gives you a structured way to do that. It defines the categories you must keep apart, the roles a supplier can occupy, the documentation to request, and a reusable question set you can apply to any supplier. It stays at an overview level on analytical testing and on the specific compounding frameworks, because those topics are large enough to deserve their own dedicated guides. Where a topic needs more depth than an overview allows, this guide says so rather than attempting it here.

One boundary to set at the outset. A Certificate of Analysis, a wholesale account, a high purity result, or the fact that a supplier sells only to physicians does not by itself establish that a given product may be used in patient care. There is no single permission that covers every kind of material. Whether any lawful route to patient use exists, and what conditions it carries, depends on the category of material, the supply pathway, the specific product and formulation, and its intended use. That is a regulatory question for qualified counsel. Whether a product is clinically appropriate for a particular patient is a separate, clinical question. Neither is something a sales relationship settles.

What does "peptide supplier" actually mean?

"Peptide supplier" is not one kind of business. The term covers entities with very different obligations, and the differences change what you should expect and verify.

Common examples include a state-licensed compounding pharmacy, a registered outsourcing facility, a distributor of finished products, a manufacturer or seller of bulk drug substance, and a seller of material labeled for research use only. That list is not exhaustive, and the roles are not always separate: one business can hold more than one role, and its role can differ from one product to the next. What matters is that each role carries its own obligations. The obligations that attach to a compounding pharmacy are not the obligations that attach to a bulk-substance manufacturer, and a distributor is not necessarily the party that made or tested the material. If you cannot say which role a prospective supplier occupies for the product you would buy, you cannot yet evaluate it, because you do not know which rules and which documentation should apply.

So the first task in any evaluation is identification. Ask the supplier to state plainly what role it occupies, who actually manufactures the material, and who may receive it. Treat a vague or shifting answer as a finding in itself.

Which category of material is being offered?

Keep four categories distinct, because they carry different legal meaning and different limits. They are not synonyms.

• FDA-approved finished drugs. FDA approval attaches to a specific finished drug product. An approval for one finished drug is not an approval for every product that contains the same named substance.
• Compounded preparations. FDA states plainly that "Compounded drugs are not FDA-approved," and that "FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed" [1].
• Bulk drug substances, sometimes referred to as active pharmaceutical ingredient. A bulk substance is an ingredient, not a finished, approved drug. Where bulk substances are used in compounding, FDA attaches defined conditions to that use, discussed below.
• Research-use-only material. Material carrying a research-use label is not, by virtue of the label alone, placed outside drug regulation.

That last point is worth stating carefully, because it is a common misreading. A disclaimer on a label does not control how a product is regulated. In a February 2025 warning letter to a peptide seller, FDA addressed products labeled "research use only," "not for human consumption," and "lab purposes only," and nonetheless concluded that "evidence obtained from your website establishes that certain products offered for sale ... are drugs intended for human use," because the products were "drugs within the meaning of section 201(g) of the FD&C Act because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease" [4]. The lesson for a buyer is not that every research-labeled product is misused. It is that the label is not the end of the analysis, and that evidence of how a product is marketed can bear on its intended use.

For your evaluation: make the supplier tell you which category applies to the specific product you would buy, and do not let a product drift between categories depending on which question you ask.

What kind of entity is the supplier, and is it registered or licensed where that matters?

The supplier's role and the category of material together determine which registration, licensing, and documentation questions apply. Neither one settles the other, so establish both and then check that what the supplier says about itself matches.

Two compounding frameworks illustrate why this matters, at an overview level. In FDA's words, "Drugs compounded in outsourcing facilities are subject to current good manufacturing practice (CGMP) requirements. By contrast, drugs compounded by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a physician, in accordance with the conditions of section 503A of the FD&C Act, are not" [1]. That is a real difference in the standards that apply, and it depends on the framework under which the compounding occurs.

When bulk drug substances are involved, the conditions are specific. Under section 503A, a bulk drug substance a compounder uses must "Comply with an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph if one exists," or be a component of an FDA-approved drug product if no monograph exists, or "Appear on FDA's list of bulk drug substances that can be used in compounding (the 503A bulks list)"; and such bulk substances "must be accompanied by a valid certificate of analysis and must have been manufactured by an establishment registered with FDA" [2]. For outsourcing facilities under section 503B, the facility "may not compound a drug product that includes a bulk drug substance unless" the substance "appears on a list identifying bulk drug substances for which there is a clinical need (the 503B bulks list)" or the compounded product is on FDA's drug shortage list, and the bulk substance likewise "must be accompanied by a valid certificate of analysis and must have been manufactured by an establishment registered with FDA under section 510" [3].

At the evaluation stage, the practical point is narrower: identify what the supplier claims to be, then check that the registration, licensing, and documentation that should accompany that role are actually present and verifiable. The detailed comparison of the two frameworks, and how to look up a substance's current status, are large topics that belong in separate, dedicated guides rather than here.

What documentation should a practice require?

Request documentation matched to the material category, and know what each document does and does not establish before you rely on it.

A Certificate of Analysis is the document most buyers ask about first. It is useful, and for bulk drug substances used in compounding under section 503A or 503B, FDA lists a valid certificate of analysis among the conditions [2][3]. That condition is specific to that context; it is not a general statement about every product category. A COA also has limits that matter to a buyer. A COA does not by itself prove regulatory compliance, clinical suitability, or the quality of every unit you receive. When a COA is present, the questions that make it meaningful are whether it is tied to the specific lot you are buying, which laboratory produced it, what was actually tested, whether the tested sample was raw material or finished product, and how the sample was selected. Reading and authenticating a COA in that level of detail is its own task and a separate subject; here, the point is to request the document, confirm it is lot-specific, and understand that its presence is a starting point rather than a verdict.

Beyond the COA, ask who manufactured the material, who may receive it, and what lot or batch identifier links the paperwork to the physical product in front of you. Lot and batch linkage is what lets you connect a document to a shipment and, later, to any quality inquiry or recall; the mechanics of tracing a lot through records are a separate subject.

What can testing establish, at a glance?

Different tests answer different questions, and it is a mistake to let one number stand in for all of them. Keep the attributes distinct.

Identity, purity, assay or content, potency, sterility, and endotoxin are not the same thing, and a result for one does not stand in for another. FDA's own vocabulary reflects this separation. Its analytical-methods guidance, written for drug applicants, describes analytical data as supporting "the documentation of the identity, strength, quality, purity, and potency of drug substances and drug products" [5]. That list names attributes; it is not a description of what any particular supplier's testing covers, and it does not address sterility or endotoxin, which are separate questions again.

A few limits are worth stating plainly, because conflating them is a common error:

• A high-performance liquid chromatography (HPLC) area percentage does not by itself establish milligrams per vial, biological potency, sterility, the absence of all impurities, or safety for injection. It speaks to a narrow question and does not answer those others.
• Purity testing does not establish sterility or endotoxin levels, and sterility testing and endotoxin testing are distinct tests, not one combined assurance.
• When a supplier describes its testing as third-party, the label alone does not tell you what was established. Ask which laboratory performed the testing, what its relationship to the seller is, which tests were in scope, and how the sample was selected.

This guide deliberately stays at this overview level. The detailed treatment of HPLC and mass spectrometry, the distinctions among purity, identity, content, and potency, and what third-party testing can and cannot establish are each large enough to warrant their own guides, and that is where the method-level detail belongs. For a buyer evaluating a supplier, the operational takeaway is simpler: ask which attribute each result actually speaks to, and do not accept one test as proof of a different property.

A supplier-evaluation question set

The table below is the practical core of this guide. It maps each evaluation criterion to a question to put to the supplier, the evidence to request, and the deeper topic it connects to. Use it as a checklist you can apply to any prospective supplier, regardless of its marketing.

The table's value is that it forces category identification and evidence matching before a commercial decision, and routes each deep question to where it belongs.

When to involve counsel or a qualified reviewer

Some questions in a supplier evaluation are legal or clinical determinations, not purchasing judgments, and they should be escalated rather than assumed.

Whether a specific product may be used in patient care is the clearest example. A physician customer, a wholesale account, a COA, or a high purity result does not by itself answer that question. The answer depends on the specific product, formulation, intended use, and supply pathway, and the regulatory assessment belongs with qualified regulatory counsel. Whether the product is clinically appropriate for a given patient is a separate clinical judgment. Likewise, the analytical questions, which method addresses which attribute and what a given result does and does not support, benefit from a qualified analytical reviewer.

A practical rule: when an answer would commit your practice to using a material clinically, or would rest on a claim about a product's regulatory status, treat that as a point to verify with an appropriate professional rather than a box the supplier can check for you.